Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer

Open-label, Dose-escalation, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre Efficacy of BVAC-C in Patients With Multiple Metastatic Progressive or Recurrent HPV Type 16 or 18 Positive Cervical Cancer After Failure to Standard Care

BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts. Phase I is for safety evaluation, and Phase IIa is for efficacy assessment.

Study Overview

• Status: Completed
• Conditions: Uterine Cervical Neoplasms
• Intervention / Treatment: Drug: Topotecan; Drug: BVAC-C

Detailed Description

BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts(Phase I, Phase II). Phase I study is Open-label, dose-escalation, multiple dosing study to evaluate the safety, tolerability, immune response and preliminary efficacy of BVAC-C in patients with multiple metastatic progressive or recurrent HPV type 16 or 18 positive cervical cancer after failure to standard care. 9~18 patients will be enrolled In Phase IIa study, which Open-label, sequential assignment multiple dosing study, efficacy, immune response and safety will be evaluated. Total 21 patients will be enrolled in 3 groups.

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of
    • Samsung Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Patients with multiple metastatic progressive or recurrent HPV type 16 or 18 positive cervical cancer
• Patients has received 1 or more platinum based doublet chemotherapy as prior therapy for progressive or recurrent tumor lesion (prior therapy does not include platinum chemotherapy given with radiation therapy for 1st line treatment before progression or recurrence)
• Patients with at least 1 measurable lesion according to RECIST
• Female patients between ages of 20 to 70
• Patients with ECOG performance status between 0 to 2

• Patients meets the blood test standards in the screening test

  • ANC≥1500/μL
  • LLN ≤ALC ≤ULN
  • Platelets≥100,000/μL
  • Hemoglobin> 9g/dL

• Patients meets the blood chemistry test standards in the screening test

  • Serum creatinine ≤ 2.0 mg/dL
  • Calculated creatinine clearance ≥ 50 mL/min
  • Serum bilirubin ≤1.5 x ULN
  • ALT and AST ≤2.5 × ULN (≤ 5 x ULN in patients with liver metastases)
• Patients who has agreed to a medically accepted contraceptive in this clinical trial
• Patients at least three months or more of survival can be expected
• Patients decided to participate in this clinical trial and signed written informed consent

Exclusion Criteria:

• Patients histopathology is a neuroendocrine or small cell carcinoma
• Patients with a history of brain metastasis or signs of brain metastasis
• Patients tested positive in serological tests for hepatitis C virus or hepatitis B virus surface antigen, (HBsAg) or human immunodeficiency virus (HIV)
• Patients with a history of HIV infection
• Patients showing abnormal electrocardiogram , including arrhythmia
• Patients have been administered the drug for other clinical trials within 4weeks before the screening visit
• Patients have been administered any vaccines within 4weeks before the screening visit (eg. hepatitis A, hepatitis B, influenza, Td, etc. )
• Patients have been administered the blood products within 3 months before the screening visit
• Patients have received chemotherapy or radiation therapy within 4weeks before the 1st administration of investigational drug (BVAC-C)
• Patients treated with immunosuppressant or immunomodulatory agents within 6 months before the screening visit
• Patients who have participated in the clinical trial of a therapeutic vaccine or immune therapy within 1 year before the screening visit
• Patients with a history of serious allergic disease or serious side effects of the drug
• Patients who is pregnant or breast-feeding
• Patients researchers has determined that participation in the clinical trial is inappropriate
• Patients suspected to have other primary cancer

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BVAC-C mono(High dose); BVAC-C IV injection at 0, 4, 8th weeks.(HIgh dose)	Drug: BVAC-C; Autologous B cells and monocytes transfected with E6E7 gene of HPV
Experimental: BVAC-C mono(Intermediate dose); BVAC-C IV injection at 0, 4, 8, 12th weeks.(Half dose)	Drug: BVAC-C; Autologous B cells and monocytes transfected with E6E7 gene of HPV
Experimental: BVAC-C + Topo Combi; BVAC-C IV injection at 0,4,8,12th weeks.(Half dose) Topotecan IV injection at 2, 6, 10, 14th weeks	Drug: Topotecan; Drug: BVAC-C; Autologous B cells and monocytes transfected with E6E7 gene of HPV

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate DLT with Clinical laboratory tests [Safety]	Lymphocyte subset, Serum cytokine, NKT/NK cell assay, CD4/CD8 assay	12th week from first injection (End of trial)
Incidence of Serious Adverse Events assessed with CTCAE [Safety]		12th week from first injection (End of trial)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical laboratory tests	Blood chemistry, Serology	Screening visit and every 2 weeks from first injection (up to 12th week)
12-lead ECG		Screening visit and Termination visit (12th week from first injection)
Vital signs	Blood pressure, Pulse rate, Respiratory rate, Tympanic temperature	Every 2 weeks from first injection (up to 12th week)
Physical examination	Body weight	Screening, 6th week from first injection, 10th week from first injection and Termination visit (12th week from first injection)

Collaborators and Investigators

• Sponsor: Cellid Co., Ltd.
• Investigators: Study Chair: C Y Kang, PH.D, Seoul National University

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2016
• Primary Completion (Actual): December 1, 2021
• Study Completion (Actual): June 1, 2022

Study Registration Dates

• First Submitted: August 9, 2016
• First Submitted That Met QC Criteria: August 12, 2016
• First Posted (Estimate): August 15, 2016

Study Record Updates

• Last Update Posted (Actual): October 12, 2022
• Last Update Submitted That Met QC Criteria: October 10, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: HPV; Type 16, 18; E6E7; Immune therapeutic vaccine
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Cervical Diseases; Uterine Diseases; Uterine Cervical Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase Inhibitors; Topoisomerase I Inhibitors; Topotecan
• Other Study ID Numbers: BVAC-C-P1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided